Medication undertreatment in assisted living settings.
暂无分享,去创建一个
Sheryl Zimmerman | Mary Roth | Lea C. Watson | Malaz Boustani | Mary T. Roth | M. Boustani | S. Zimmerman | P. Sloane | J. Magaziner | A. Gruber-Baldini | J. Hebel | Jay Magaziner | Ann L Gruber-Baldini | J Richard Hebel | Philip D Sloane | Lea Watson | J. Hebel | J. R. Hebel | Ann L. Gruber-Baldini
[1] Jaakko Tuomilehto,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .
[2] J. Potter,et al. Heart Failure: Evaluation and Treatment of Patient's with Left Ventricular Systolic Dysfunction , 1998, Journal of the American Geriatrics Society.
[3] D W Bates,et al. Incidence and preventability of adverse drug events in nursing homes. , 2000, The American journal of medicine.
[4] Randall S Stafford,et al. The underutilization of cardiac medications of proven benefit, 1990 to 2002. , 2003, Journal of the American College of Cardiology.
[5] M. Beers,et al. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. , 1997, Archives of internal medicine.
[6] Y. Stern,et al. Mortality in patients with dementia after ischemic stroke , 2002, Neurology.
[7] L. Lipsitz,et al. Correlates and Management of Nonmalignant Pain in the Nursing Home , 1999, Journal of the American Geriatrics Society.
[8] Guidelines for Medical Treatment for Stroke Prevention , 1994, Annals of Internal Medicine.
[9] G P Samsa,et al. Adverse Drug Events In High Risk Older Outpatients , 1997, Journal of the American Geriatrics Society.
[10] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[11] V. Hasselblad,et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. , 1999, Archives of internal medicine.
[12] J. Alpert,et al. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. , 1992, The American journal of medicine.
[13] A. Hildreth,et al. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. , 1998, Respiratory medicine.
[14] D. Brand,et al. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.
[15] V. Hachinski,et al. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. , 1997, Archives of neurology.
[16] M. Paik,et al. Treatment for the Secondary Prevention of Stroke in Older Patients: The Influence of Dementia Status , 1999, Journal of the American Geriatrics Society.
[17] W. Aronow,et al. Underutilization of Beta‐Blockers in Older Patients With Prior Myocardial Infarction or Coronary Artery Disease in an Academic, Hospital‐Based Geriatrics Practice , 1997, Journal of the American Geriatrics Society.
[18] G E Dallal,et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.
[19] L. Lipsitz,et al. Management of heart failure among very old persons living in long-term care: Has the voice of trials spread? , 2000 .
[20] G. Lamas,et al. Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. , 1999, Journal of the American Geriatrics Society.
[21] D. Bates,et al. Risk factors for adverse drug events among nursing home residents. , 2001, Archives of internal medicine.
[22] R. Califf,et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[23] P. Deedwania,et al. Effects of Treatment on Outcome in Mildly Symptomatic Patients With Ischemia During Daily Life: The Atenolol Silent Ischemia Study (ASIST) , 1994, Circulation.
[24] W. Thies,et al. Fighting heart disease and stroke. Recommendations of the AHA Stroke Positioning Task Force. , 1998, Stroke.
[25] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[26] J. Gurwitz,et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. , 2001, Archives of internal medicine.
[27] H. Meyer. The bottom line on assisted living. , 1998, Hospitals & health networks.
[28] S. Yusuf,et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.
[29] H. Meyer. The right to appeal. , 1998, Hospitals & health networks.
[30] F. Avanzini,et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators. , 1997, European heart journal.
[31] M. Llorente,et al. Inappropriate Medication Prescribing in Homebound Older Adults , 1999, Journal of the American Geriatrics Society.
[32] B. Dawson-Hughes,et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women , 1991, The New England journal of medicine.
[33] B. Henderson,et al. Menopausal estrogen therapy and hip fractures. , 1982, Annals of internal medicine.
[34] H. Krumholz,et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.
[35] D. Himmelstein,et al. Inappropriate drug prescribing for the community-dwelling elderly. , 1994, JAMA.
[36] B. Zarowitz,et al. The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction. , 1993, Progress in cardiovascular diseases.
[37] Mark A. Hlatky,et al. Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .
[38] H. Genant,et al. Long-term estrogen replacement therapy prevents bone loss and fractures. , 1985, Annals of internal medicine.
[39] C. Gatsonis,et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. , 1998, JAMA.
[40] K. Swedberg,et al. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. , 1996, The American journal of cardiology.
[41] H. Morgenstern,et al. Inappropriate Medication Prescribing in Skilled-Nursing Facilities , 1992, Annals of Internal Medicine.
[42] S. Zimmerman,et al. End‐of‐Life Care in Assisted Living and Related Residential Care Settings: Comparison with Nursing Homes , 2003, Journal of the American Geriatrics Society.
[43] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[44] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[45] S. Zimmerman,et al. Inappropriate Medication Prescribing in Residential Care/Assisted Living Facilities , 2002, Journal of the American Geriatrics Society.
[46] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[47] J. Avorn,et al. Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. , 1999, Journal of clinical epidemiology.
[48] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[49] P. Rochon,et al. Prescribing for seniors: neither too much nor too little. , 1999, JAMA.
[50] D. Bates,et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.
[51] N. Weiss,et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. , 1980, The New England journal of medicine.
[52] D. Massel,et al. Report of the Canadian Cardiovascular Society's consensus conference on the Management of the Postmyocardial Infarction Patient. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[53] Jeffrey M. Hausdorff,et al. Undertreatment of Cardiovascular Disease in Ethnically Diverse Older Adults: Who Should Receive an Electrocardiogram? , 2001, Journal of the American Geriatrics Society.
[54] E. Antman,et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.
[55] K. Parker,et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. , 1998, Archives of internal medicine.
[56] Estrogen Replacement Therapy and Fractures in Older Women , 1995 .
[57] A. Wall,et al. Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .
[58] C. Ambrose,et al. Undertreatment of osteoporosis in men with hip fracture. , 2002, Archives of internal medicine.
[59] J. Avorn,et al. Epidemiology of Adverse Drug Events in the Nursing Home Setting , 1995, Drugs & aging.
[60] Richard P. Lewis,et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[61] Sidney C. Smith,et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.
[62] J. Aloia,et al. Calcium Supplementation with and without Hormone Replacement Therapy To Prevent Postmenopausal Bone Loss , 1994, Annals of Internal Medicine.
[63] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[64] P. Sloane,et al. The MDS Cognition Scale: A Valid Instrument for Identifying and Staging Nursing Home Residents with Dementia Using the Minimum Data Set , 1994, Journal of the American Geriatrics Society.
[65] H. Perry,et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. , 2000, The American journal of medicine.
[66] John C. Beck,et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. , 1991 .